Neurol. praxi. 2011;12(6):384-388

Basic principles of corticosteroid treatment in autoimmune neuromuscular disorders

doc.MUDr.Peter Špalek, PhD.
Centrum pre neuromuskulárne ochorenia, Neurologická klinika SZU, Bratislava&ndash,Ružinov

Corticosteroids are the most widely and frequently used immunomodulatory agents. The immunosuppressive and anti-inflammatory

effects of corticosteroids have several components. Corticosteroids induce peripheral blood neutrophilia, whereas T-cells, monocytes,

and eosinophils are depleted from blood. Steroids alter functional properties of T-cells and monocytes, act on synthesis and secretion of

cytokines and immune mediators, and have effect on microvascular permeability. For autoimmune neuromuscular diseases treatment with

corticosteroids can be extended over many years (e.g., myasthenia gravis, polymyositis, dermatomyositis, CIDP, etc), for other diseases

corticosteroid treatment is limited to a short period time (e.g., multiple sclerosis). An aggressive approach with high-dose prednisone

beginning early in the diseases is recommended. A high dose of at least 1 mg/kg as a single daily morning dose in initial period is prefered.

Treatment with corticosteroids can be associated with side reactions. When corticosteroid treatment becomes mandatory, efforts

must focus on minimizing corticosteroids side effects while maintaining therapeutic efficacy. The single-dose, alternate-day program

minimizes adverse effects while adequately maintaining control of underlying disease.

Keywords: corticosteroids, mechanism of action, treatment, general principles, side effects

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špalek P. Basic principles of corticosteroid treatment in autoimmune neuromuscular disorders. Neurol. praxi. 2011;12(6):384-388.
Download citation

References

  1. Bedlack RS, Sanders DB. Steroid treatment for myasthenia gravis: steroids have an important role. Muscle Nerve 2002; 25: 117-121. Go to original source... Go to PubMed...
  2. Bronner IM, Hoogendijk JE, Wintzen AR, van der Meulen MFG, Wokke JHJ, de Visser M. Necrotising myopathy, an unusual presentation of steroid-resposive myopathy. J Neurol 2003; 250: 480-485. Go to original source... Go to PubMed...
  3. Distad BJ, Amato AA, Weiss MD. Inflammatory Myopathies. Curr Treat Opt Neurol 2011; 13: 119-130. Go to original source... Go to PubMed...
  4. Gold R, Dalakas MC, Toyka KV. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurology 2003; 2: 22-32. Go to original source... Go to PubMed...
  5. Gold R, Hartung H-P, Heuss DF, Kieseier B, Koeppen S, Reinhold-Keller E, Sommer C, Stoll G, Toyka KV, Bischoff C, Grisold W, Steck A. Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden. In: Leitlinien für Diagnostik und Therapie in der Neurologie. Ed. Diener HC, Putzki N. Stutthart, George Thieme Verlag 2008; 476-485.
  6. Hohlfeld R, Dalakas MC. Basic principles of immunotherapy for neurologic diseases. Sem Neurol 2003; 23: 121-131. Go to original source... Go to PubMed...
  7. Jani-Acsadi A, Lisak RP. Myasthenia gravis. Curr Treatment Options Neurol 2010; 12: 231-243. Go to original source... Go to PubMed...
  8. Lopate G, Pestronk A. Inflammatory demyelinating neuropathies. Curr Treat Opt Neurol 2011; 13: 131-142. Go to original source... Go to PubMed...
  9. Markham LW, Kinnett K, Wong BL, Woodrow BD, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008; 18: 365-370. Go to original source... Go to PubMed...
  10. Palace J, Newsom-Davis J, Lecky B, the Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50: 1778-1883. Go to original source... Go to PubMed...
  11. Seybold M, Drachman D. Gradually increasing doses of prednisone in myasthenia gravis: reducing hazards of treatment. N Engl J Med 1974; 290: 81-84. Go to original source... Go to PubMed...
  12. Špalek P. Myasténia gravis. Čes Slov Neurol Neurochir 2008; 71/104: 7-23.
  13. Špalek P. Zánětlivé myopatie - patogeneze, diagnostika a léčba. Postgrad Med 2008; 10: 926-936.
  14. Špalek P. Lambert-Eatonov myastenický syndróm - patogenéza, diagnostika a liečba. Neurológia 2009; 4: 161-165.
  15. Špalek P. Kortikoterapia autoimunitných neurologických ochorení - základné princípy a profylaxia nežiadúcich účinkov. Neurol pre prax 2010; 11(Suppl 1): 26-27.
  16. Špalek P, Kurča E. Imunoterapia CIDP. Ces Slov Neurol Neurochir 2010; 106(73): 468-469.
  17. Špalek P, Schnorrer M, Krajč T. Diagnostika a liečba paraneoplastickej myasténie gravis asociovanej s tymómom. Neurológia 2010; 5: 79-85.
  18. Špalek P. Akútne myelitídy - etiológia, diagnostika a liečba. Neurologie pro prax 2011; 12: 36-41.
  19. Šteňová E, Koreň M. Systémová kortikoterapia - špecifiká liečby glukokortikoidmi. Amb ter 2009; 7: 38-42.
  20. Thaera GM, Wellik KE, Barrs DM, Dunckley ED, Wingerschuk DM, Demaerschalk BM. Are corticosteroid and antiviral treatments effective for Bell palsy? A critically appraised topic. Neurologist 2010; 16: 138-140. Go to original source... Go to PubMed...
  21. Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, Prsytowsky S. Neurosarcoidosis: presentations and management. Neurologist 2010; 16: 2-15. Go to original source... Go to PubMed...
  22. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurology 2010; 9: 402-412. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.